Full-Spectrum Hemp (CBD)

The upside comes overwhelmingly from neurological and acute-anxiety effects, anchored by the strongest possible human evidence for one use and respectable evidence for another. The single strongest study here is Devinsky 2017, a double-blind RCT showing purified CBD cut seizures dramatically, which led to FDA approval. The key boundary condition runs through the whole report: that landmark evidence is for high-dose purified CBD, while consumer full-spectrum products are lower-dose and less studied, so the upside is real but narrower than the category's marketing implies.

Efficacy (3.2/5.0): The strongest real-world clinical magnitude is in epilepsy: Devinsky 2017 cut monthly convulsive seizures by 39% versus 13% on placebo in 120 Dravet patients, and Devinsky 2018 replicated a 41.9% drop-seizure reduction in Lennox-Gastaut. For anxiety, a single 600 mg dose normalized public-speaking anxiety in Bergamaschi 2011. These are large, meaningful effects. But the population that actually buys full-spectrum hemp uses it for general wellness at far lower doses where the demonstrated magnitude is modest, so efficacy averages to a moderate 3.2 across core uses rather than the high end the seizure data alone would suggest.

Breadth of Benefits (3.3/5.0): CBD touches several systems with at least some human signal. The central nervous system is the clear win, with seizure control (convulsive and drop seizures) and acute anxiety reduction. There is a plausible mood and stress-resilience reach through 5-HT1A activity. Beyond the CNS, the picture weakens fast: chronic pain shows an inconsistent signal per Villanueva 2022, and gut, immune, cardiovascular, and skin uses rest mostly on preclinical work. So the breadth is genuine but front-loaded onto neurology and anxiety, with the wider wellness claims thinly evidenced.

Evidence Quality (3.4/5.0): This is unusual for a supplement: one indication has pharmaceutical-grade proof. Two double-blind RCTs by Devinsky and colleagues in 2017 and 2018, plus FDA approval, put the seizure evidence at the top of the ladder. Acute anxiety adds smaller real RCTs. The WHO 2018 critical review confirms a well-characterized safety profile. The drag comes from the consumer uses: chronic pain reviews are equivocal and low-certainty, sleep evidence is uncontrolled, and the entourage effect is explicitly unproven per Christensen 2023. Averaged across the core indications, the evidence is solid-with-gaps at 3.4.

Speed of Onset (3.5/5.0): CBD is reasonably fast where it works. Acute anxiety effects appear within about 1.5 to 2 hours of an oral dose, matching the dosing window in the public-speaking RCTs, and sublingual oil can act faster. Seizure benefit builds over 2 to 4 weeks of daily dosing rather than appearing immediately. This mix of an acute situational effect plus a manageable chronic build earns an above-neutral 3.5.

Durability (3.2/5.0): In epilepsy, the seizure benefit is sustained with continued daily dosing and tolerance is not a major problem, which is a genuine durability strength. For anxiety, most evidence is single-dose, so durable chronic benefit is less established. Effects require ongoing use rather than persisting after stopping. The result is a moderate 3.2: durable where studied long-term, unproven for daily wellness maintenance.

Bioindividuality Upside (3.0/5.0): Response varies widely, which cuts both ways. Strong responders include people with the specific epilepsy syndromes studied and those with acute situational anxiety. Weak responders are common in the general-wellness crowd, partly because low oral bioavailability (roughly 6 to 19%) and inconsistent product dosing mean two people on the same labeled dose can absorb very different amounts. Because there are few validated biomarkers to predict response in advance, bioindividuality sits at a neutral 3.0: real responder variation, limited ability to target it.